Analyze Diet

Topic:Immunization

Immunization in horses involves the administration of vaccines to stimulate an immune response, thereby providing protection against specific infectious diseases. Vaccines commonly used in equine medicine include those for equine influenza, tetanus, and West Nile virus. The process of immunization aims to prepare the horse's immune system to recognize and combat pathogens upon exposure. Vaccination schedules and protocols may vary based on factors such as age, health status, and regional disease prevalence. This page compiles peer-reviewed research studies and scholarly articles that explore the mechanisms, efficacy, and considerations of immunization practices in equine health.
Recombinant Streptococcus equi proteins protect mice in challenge experiments and induce immune response in horses.
Infection and immunity    May 25, 2004   Volume 72, Issue 6 3228-3236 doi: 10.1128/IAI.72.6.3228-3236.2004
Flock M, Jacobsson K, Frykberg L, Hirst TR, Franklin A, Guss B, Flock JI.Horses that have undergone infection caused by Streptococcus equi subspecies equi (strangles) were found to have significantly increased serum antibody titers against three previously characterized proteins, FNZ (cell surface-bound fibronectin binding protein), SFS (secreted fibronectin binding protein), and EAG (alpha2-macroglobulin, albumin, and immunoglobulin G [IgG] binding protein) from S. equi. To assess the protective efficacy of vaccination with these three proteins, a mouse model of equine strangles was utilized. Parts of the three recombinant proteins were used to immunize mice, eith...
Evaluation of immune responses in horses immunized using a killed Sarcocystis neurona vaccine.
Veterinary therapeutics : research in applied veterinary medicine    May 20, 2004   Volume 5, Issue 1 34-42 
Marsh AE, Lakritz J, Johnson PJ, Miller MA, Chiang YW, Chu HJ.Clinically normal horses developed cellular immunity to Sarcocystis neurona following IM vaccination with a commercial killed S. neurona vaccine, as indicated by the development of measurable anti-S. neurona IgG antibodies and additional intradermal skin testing. Large-scale independent assessments of the vaccine's performance and safety are in progress under field conditions. The next step in the evaluation of this vaccine would be to attempt experimental challenge after a reproducible reliable equine model of S. neurona encephalitis has been established that allows for reisolation of the pat...
Equine seminal plasma reduces sperm binding to polymorphonuclear neutrophils (PMNs) and improves the fertility of fresh semen inseminated into inflamed uteri.
Reproduction (Cambridge, England)    May 7, 2004   Volume 127, Issue 5 593-600 doi: 10.1530/rep.1.00096
Alghamdi AS, Foster DN, Troedsson MH.Seminal plasma (SP) is known to have immunosuppressive properties in several species. Equine SP has been reported to reduce or inhibit chemotaxis, phagocytosis and complement activity in vitro. The type and amount of the SP component that suppresses sperm-polymorphonuclear neutrophil (PMN) binding in vitro was determined, and the effect of such suppression on the fertility of mares inseminated in the presence of uterine inflammation, was analyzed. Sperm cells were suspended in either SP, semen extender or a mixture of both, and each was mixed with PMN-rich uterine secretions collected at 12 h ...
Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge.
Archives of virology. Supplementum    May 4, 2004   Issue 18 221-230 doi: 10.1007/978-3-7091-0572-6_20
Minke JM, Siger L, Karaca K, Austgen L, Gordy P, Bowen R, Renshaw RW, Loosmore S, Audonnet JC, Nordgren B.An ALVAC (canarypoxvirus)-based recombinant (vCP2017) expressing the prM and E genes derived from a 1999 New York isolate of West Nile virus (WNV) was constructed and assessed for its protective efficacy in horses in two different experiments. In the first trial, a dose titration study was conducted to evaluate both serum neutralising antibody responses to WNV and duration of immunity. In the second trial the onset of protection was determined. Twenty-eight adult horses received two doses of vCP2017 administered intramuscularly at 5-week intervals and sixteen horses comprised age-matched non-v...
Prospects for vaccination against equine grass sickness.
Equine veterinary journal    March 25, 2004   Volume 36, Issue 2 186-191 doi: 10.2746/0425164044868710
Hedderson EJ, Newton JR.Their is both historical and modern scientific evidence to support the hypothesis that equine grass sickness (EC'S) is caused by a toxico-infectious form of botulism involving a Clostridium botulism type C toxin 1114 is produced locally within the gastrointestinal tract of affected horses (Toc her et al. 1923: Tneher 1924: Hunter a aL 1999: Hunter and anion 2001: McCarthy 2002: McCarthy a aL 201)4a1. This report concerns a meeting convened to review the current state of knowledge and possible strategies for vaccination against EGS. including historical. clinical and pathological aspects of the...
Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination.
Veterinary immunology and immunopathology    March 11, 2004   Volume 98, Issue 3-4 127-136 doi: 10.1016/j.vetimm.2003.11.004
Breathnach CC, Rudersdorf R, Lunn DP.Recombinant modified vaccinia Ankara (MVA) vectors expressing equine influenza virus genes were constructed and evaluated for use in equine vaccination. Two strains of recombinant MVA, expressing either hemagglutinin (HA) or nucleoprotein (NP) genes were constructed. Each influenza virus gene was cloned from A/equine/Kentucky/1/81 (Eq/Ky) into an MVA construction plasmid, and was introduced to the deletion III locus of the wild type MVA genome by homologous recombination. Recombinant viruses were plaque purified, and antigen expression was confirmed by immunostaining. Two ponies were primed by...
Immunogenecity of synthetic peptides representing linear B-cell epitopes of VapA of Rhodococcus equi.
Vaccine    March 9, 2004   Volume 22, Issue 9-10 1114-1123 doi: 10.1016/j.vaccine.2003.10.006
Taouji S, Nomura I, Giguère S, Tomomitsu S, Kakuda T, Ganne V, Takaï S.Amino acid 65-78 of membrane protein VapA of the facultative intracellular Rhodococcus equi contained an immunodominant N-terminal B-cell epitope (N15Y peptide). Safety and immunogenecity of a synthetic peptide consisting of the amino acid 65-78 of VapA (peptide N15Y) were evaluated first in mice and in healthy adult horses. A single dose of a peptide-VapA vaccine induced and only in presence of adjuvant, specific IgG antibodies in sera of mice. After challenge with virulent R. equi 3 weeks after immunization, tissue clearance was more delayed in immunized mice than in control mice. An antibod...
Updating equine influenza strains in a combined equine influenza and herpesvirus vaccine.
Veterinary journal (London, England : 1997)    February 21, 2004   Volume 167, Issue 2 118-120 doi: 10.1016/S1090-0233(03)00034-0
Cullinane AA.No abstract available
Effect of active immunization of pony mares against recombinant porcine inhibin alpha subunit on ovarian follicular development and plasma steroids and gonadotropins.
The Journal of veterinary medical science    February 13, 2004   Volume 66, Issue 1 31-35 doi: 10.1292/jvms.66.31
Derar RI, Maeda Y, Hoque SM, Osawa T, Watanabe G, Taya K, Miyake Y.Two pony mares were immunized against recombinant porcine inhibin alpha subunit three times with 39 day intervals. Clinical findings and endocrinological changes before immunization were taken as the control. The first significant rise in the anti-inhibin titre (P<0.05) in the circulation was found 27 days after the first injection. Maximum binding activity was reached by the 12th day after the second booster dose. The number of small, medium and large sized follicles had increased significantly compared to before immunization (11.75 +/- 4.30, 2.75 +/- 0.69 and 2.51 +/- 0.63 vs 6.50 +/- 1.4...
Sarcocystis neurona-specific immunoglobulin G in the serum and cerebrospinal fluid of horses administered S neurona vaccine.
Journal of veterinary internal medicine    February 10, 2004   Volume 18, Issue 1 98-103 doi: 10.1892/0891-6640(2004)18<98:snigit>2.0.co;2
Witonsky S, Morrow JK, Leger C, Dascanio J, Buechner-Maxwell V, Palmer W, Kline K, Cook A.A vaccine against Sarcocystis neurona, which induces equine protozoal myeloencephalitis (EPM), has received conditional licensure in the United States. A major concern is whether the immunoglobulin G (IgG) response elicited by the vaccine will compromise the use of Western blotting (WB) as a diagnostic tool in vaccinated horses with neurologic disease. Our goals were to determine if vaccination (1) causes seroconversion: (2) causes at least a transient increase in S neurona-specific IgG in the cerebrospinal fluid (CSF); and (3) induces an IgG response that can be differentiated from that induc...
Equine vaccine for West Nile virus.
Developments in biologicals    December 18, 2003   Volume 114 221-227 
Ng T, Hathaway D, Jennings N, Champ D, Chiang YW, Chu HJ.To meet the urgent need of controlling West Nile virus (WNV) infection in the equine population, we have developed a killed WNV vaccine. A dose titration study in horses was first conducted to evaluate serum neutralization antibody responses against WNV in these animals. Horses were vaccinated intramuscularly twice with the test vaccine at low, medium and high dose, three weeks apart. Serum samples were collected periodically and were measured for serum neutralizing antibody using a plaque reduction neutralization test. Significant increases in serum neutralizing antibody were detected in all ...
Rabies DNA vaccine in the horse: strategies to improve serological responses.
Vaccine    October 25, 2003   Volume 21, Issue 31 4593-4596 doi: 10.1016/s0264-410x(03)00504-8
Fischer L, Minke J, Dufay N, Baudu P, Audonnet JC.In order for DNA vaccines to become a practical alternative to conventional vaccines their ability to induce antibody responses in large mammals needs to be improved. We used DNA vaccination against rabies in the horse as a model to test the potential of two different strategies to enhance antibody responses in a large mammalian species. The administration of the DNA vaccine in the presence of aluminum phosphate improved both the onset and the intensity of serological responses but was not potent enough to achieve seroconversion in all vaccinated ponies. However, when the DNA vaccine was formu...
APHIS: West Nile virus vaccine safe for use.
Journal of the American Veterinary Medical Association    August 22, 2003   Volume 223, Issue 4 416-418 
Kahler SC.No abstract available
Analysis of anamnestic immune responses in adult horses and priming in neonates induced by a DNA vaccine expressing the vapA gene of Rhodococcus equi.
Vaccine    August 19, 2003   Volume 21, Issue 25-26 3815-3825 doi: 10.1016/s0264-410x(03)00329-3
Lopez AM, Hines MT, Palmer GH, Knowles DP, Alperin DC, Hines SA.Rhodococcus equi remains one of the most important pathogens of early life in horses, yet conventional vaccines to prevent rhodococcal pneumonia have not been successful. DNA vaccination offers an alternative to conventional vaccines with specific advantages for immunization of neonates. We developed a DNA vaccine expressing the vapA gene (pVR1055vapA) that induced an anamnestic response characterized by virulence associated protein A (VapA)-specific IgG antibodies in sera and bronchoalveolar lavage fluid (BALF) as well as VapA-specific proliferation of pulmonary lymphocytes when tested in adu...
Comparison of hamster and pony challenge models for evaluation of effect of antigenic drift on cross protection afforded by equine influenza vaccines.
Equine veterinary journal    July 24, 2003   Volume 35, Issue 5 458-462 doi: 10.2746/042516403775600433
Daly JM, Yates RJ, Browse G, Swann Z, Newton JR, Jessett D, Davis-Poynter N, Mumford JA.Vaccination and challenge studies in ponies are the most relevant experimental system for predicting whether strains included in equine influenza vaccines are relevant, but they are difficult to perform. Objective: In order to investigate the feasibility of using a small animal model, results of a cross-protection study in hamsters were compared with those from a previous pony challenge experiment. Methods: Animals were immunised with inactivated vaccines containing one of 4 strains of equine influenza A H3N8 subtype virus isolated over a 26 year period (1963 to 1989), then challenged with a 1...
[Expression and immunogenicity of equine infectious anemia virus membrane protein GP90]. Dai CB, Xiao Y, Lu H, Shen RX, Shao YM.Membrane protein GP90 of China equine infectious anemia virus (EIAV) vaccine strain (DLV) and its parental wild type LN strain were expressed with Bac-to-Bac baculovirus expression system and BALB/c mice were inoculated with purified protein, thereby to explore the availability of protein for differential diagnosis and potential for preparing genetically engineered vaccine. Methods: The authors infected donkey PBMC culture with China EIAV vaccine strain (DLV) and its parental wild type LN strain, extracted its proviral DNA as template, amplified the GP90 of DLV and LN, respectively, and expres...
Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain.
Journal of virology    July 15, 2003   Volume 77, Issue 15 8470-8480 doi: 10.1128/jvi.77.15.8470-8480.2003
Castillo-Olivares J, Wieringa R, Bakonyi T, de Vries AA, Davis-Poynter NJ, Rottier PJ.Equine arteritis virus (EAV) is an enveloped plus-strand RNA virus of the family Arteriviridae (order Nidovirales) that causes respiratory and reproductive disease in equids. Protective, virus-neutralizing antibodies (VNAb) elicited by infection are directed predominantly against an immunodominant region in the membrane-proximal domain of the viral envelope glycoprotein G(L), allowing recently the establishment of a sensitive peptide enzyme-linked immunosorbent assay (ELISA) based on this particular domain (J. Nugent et al., J. Virol. Methods 90:167-183, 2000). By using an infectious cDNA we h...
Immunohistochemical localization of Clostridium perfringens beta2-toxin in the gastrointestinal tract of horses.
Veterinary pathology    June 26, 2003   Volume 40, Issue 4 376-381 doi: 10.1354/vp.40-4-376
Bacciarini LN, Boerlin P, Straub R, Frey J, Gröne A.Clostridia-associated intestinal disease in horses was generally reported to be due to infection with Clostridium perfringens type A, which harbors the cpa-encoded alpha-toxin. A recent study demonstrated a high incidence of beta2-toxigenic C. perfringens in horses suffering or dying from typhlocolitis, suggesting that this novel type of C. perfringens might play an important role in typhlocolitis and possibly other equine intestinal diseases. A retrospective study was conducted to assess the presence of the beta2-toxin in tissues of the equine gastrointestinal tract. Monospecific polyclonal a...
A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses.
Journal of virology    June 14, 2003   Volume 77, Issue 13 7244-7253 doi: 10.1128/jvi.77.13.7244-7253.2003
Li F, Craigo JK, Howe L, Steckbeck JD, Cook S, Issel C, Montelaro RC.Previous evaluations of inactivated whole-virus and envelope subunit vaccines to equine infectious anemia virus (EIAV) have revealed a broad spectrum of efficacy ranging from highly type-specific protection to severe enhancement of viral replication and disease in experimentally immunized equids. Among experimental animal lentivirus vaccines, immunizations with live attenuated viral strains have proven most effective, but the vaccine efficacy has been shown to be highly dependent on the nature and severity of the vaccine virus attenuation. We describe here for the first time the characterizati...
Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates a local IgA response.
Vaccine    June 12, 2003   Volume 21, Issue 21-22 3081-3092 doi: 10.1016/s0264-410x(03)00161-0
Soboll G, Nelson KM, Leuthner ES, Clark RJ, Drape R, Macklin MD, Swain WF, Olsen CW, Lunn DP.We have previously demonstrated that equine influenza virus hemagglutinin (HA) DNA vaccination protects ponies from challenge infection, and induces protective IgGa and IgGb responses. However, this approach does not induce a nasal IgA response. The objective of this study was to examine the value of cholera toxin (CT) administration as an adjuvant for intranasal HA DNA vaccination, and to measure protection 3 months after DNA vaccination. After an immunogenic dose of CT was determined, ponies were immunized on two occasions by intranasal administration of HA DNA and cholera toxin, or HA DNA a...
[A new product in the vaccination gap: the vector vaccine. Merial introduced an innovative influenza-tetanus vaccine for horses].
Tijdschrift voor diergeneeskunde    May 29, 2003   Volume 128, Issue 9 295-296 
Hulsen J.No abstract available
Mapping epitopes in equine rhinitis A virus VP1 recognized by antibodies elicited in response to infection of the natural host.
The Journal of general virology    May 29, 2003   Volume 84, Issue Pt 6 1607-1612 doi: 10.1099/vir.0.18848-0
Stevenson RA, Hartley CA, Huang JA, Studdert MJ, Crabb BS, Warner S.Equine rhinitis A virus (ERAV) is an important respiratory pathogen of horses and is of additional interest because of its close relationship and common classification with foot-and-mouth disease virus (FMDV). As is the case with FMDV, the VP1 capsid protein of ERAV has been shown to be a target of neutralizing antibodies. In FMDV VP1, such antibodies commonly recognize linear epitopes present in the betaG-betaH loop region. To map linear B cell epitopes in ERAV VP1, overlapping fragments spanning its length were expressed in Escherichia coli as glutathione S-transferase (GST) fusion proteins....
Collaborative study for the establishment of two European Pharmacopoeia Biological Reference Preparations for serological potency testing of tetanus vaccines for veterinary use.
Developments in biologicals    April 8, 2003   Volume 111 69-76 
Lensing HH, Behr-Gross ME, Daas A, Spieser JM.The European Directorate for the Quality of Medicines (EDQM) has organised an international collaborative study, divided into two phases, aimed at producing and establishing two suitable reference sera for serological potency testing of tetanus vaccines for veterinary use for batch consistency demonstration. In phase I pools of sera were produced by immunising guinea pigs and rabbits with tetanus toxoid using the immunisation schedule prescribed by the European Pharmacopoeia (Ph. Eur.) for potency testing of tenanus vaccines for veterinary use. Following aliquoting and freeze-drying, character...
Limited potential for mosquito transmission of genetically engineered, live-attenuated western equine encephalitis virus vaccine candidates.
The American journal of tropical medicine and hygiene    March 19, 2003   Volume 68, Issue 2 218-221 
Turell MJ, O'Guinn ML, Parker MD.Specific mutations associated with attenuation of Venezuelan equine encephalitis (VEE) virus in rodent models were identified during efforts to develop an improved VEE vaccine. Analogous mutations were produced in full-length cDNA clones of the Cba 87 strain of western equine encephalitis (WEE) virus by site-directed mutagenesis in an attempt to develop an improved WEE vaccine. Isogenic viral strains with these mutations were recovered after transfection of baby hamster kidney cells with infectious RNA. We evaluated two of these strains (WE2102 and WE2130) for their ability to replicate in and...
Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge.
Infection and immunity    February 22, 2003   Volume 71, Issue 3 1491-1496 doi: 10.1128/IAI.71.3.1491-1496.2003
Lee JS, Hadjipanayis AG, Welkos SL.Anthrax, a disease usually associated with herbivores, is caused by the bacterium Bacillus anthracis. The current vaccine licensed for human use requires a six-dose primary series and yearly boosters and causes reactogenicity in up to 30% of vaccine recipients. A minimally reactogenic vaccine requiring fewer inoculations is warranted. Venezuelan equine encephalitis (VEE) virus has been configured for use as a vaccine vector for a wide variety of immunogens. The VEE vaccine vector is composed of a self-replicating RNA (replicon) containing all of the VEE virus nonstructural genes and a multiple...
Response of ELA-A1 horses immunized with lipopeptide containing an equine infectious anemia virus ELA-A1-restricted CTL epitope to virus challenge.
Vaccine    January 18, 2003   Volume 21, Issue 5-6 491-506 doi: 10.1016/s0264-410x(02)00474-7
Ridgely SL, Zhang B, McGuire TC.Lipopeptide containing an ELA-A1-restricted cytotoxic T lymphocyte (CTL) epitope from the envelope surface unit (SU) protein of the EIAV(WSU5) strain was used to immunize three horses having the ELA-A1 haplotype. Peptide-specific ELA-A1-restricted CTL were induced in all three horses, although these were present transiently in PBMC. These horses were further immunized with lipopeptide containing the corresponding CTL epitope from the EIAV(PV) strain. Then, the three immunized horses and three non-immunized horses were challenged by intravenous inoculation with 300 TCID(50) EIAV(PV). All horses...
The effect of aging on immune responses.
The Veterinary clinics of North America. Equine practice    January 9, 2003   Volume 18, Issue 3 621-ix doi: 10.1016/s0749-0739(02)00027-5
Fermaglich DH, Horohov DW.Although vaccine manufacturers make no specific recommendations regarding the vaccination of older horses and ponies, the similarities in age-induced immunologic changes between human beings and equids suggests that similar vaccination recommendations should be followed. The need for vaccination of the older horse depends, of course, on the relative risk of exposure for the individual horse. Particular care should be taken when using attenuated vaccine products because these live agents may pose a unique risk to the older individual. Immunization with inactivated agent vaccines is likely to be...
An updated equine influenza vaccine and an equine influenza-herpesvirus combination vaccine containing an immunostim adjuvant provoke equal antibody levels in young foals throughout the primary vaccination course.
Veterinary journal (London, England : 1997)    December 31, 2002   Volume 164, Issue 3 288-291 doi: 10.1053/tvjl.2002.0712
Heldens JG, Van de Wouw JC, Van Loon AA.No abstract available
The impact of a low dose, low volume, multi-site immunization on the production of therapeutic antivenoms in Thailand.
Toxicon : official journal of the International Society on Toxinology    December 7, 2002   Volume 41, Issue 1 57-64 doi: 10.1016/s0041-0101(02)00209-x
Sriprapat S, Aeksowan S, Sapsutthipas S, Chotwiwatthanakun C, Suttijitpaisal P, Pratanaphon R, Khow O, Sitprija V, Ratanabanangkoon K.Therapeutic antivenom against snakes was first produced by Albert Calmette in 1894. Since then antivenoms have saved the life of countless snakebite victims. However, there are still many problems associated with antivenom production, for example variable percentage of responder horses, low neutralizing potency of antivenom, the large amount of snake venom needed for immunization and the difficulties encountered in producing potent polyvalent antivenoms. These problems have led to shortage and high cost of antivenom and, in some cases, failure of treatment. In 1997, a new immunization protocol...
Serum and mucosal antibodies of infected foals recognized two distinct epitopes of VapA of Rhodococcus equi.
FEMS immunology and medical microbiology    November 22, 2002   Volume 34, Issue 4 299-306 doi: 10.1111/j.1574-695X.2002.tb00637.x
Taouji S, Bréard E, Peyret-Lacombe A, Pronost S, Fortier G, Collobert-Laugier C.Virulence-associated protein A (VapA) of Rhodococcus equi has been proposed for use both as a vaccine and as a target for antibodies in immunotherapy and diagnostic tests. Epitope mapping of VapA allowed the identification of two B cell epitopes associated with R. equi pneumonia. The peptide NLQKDEPGRASDT was confirmed as an immunodominant N-terminal B cell epitope recognized by all sera from infected foals while VSFQYNAVGPYLNINFFDSS (C-terminal B cell epitope) was exclusively recognized by IgA from the tracheal aspirates. Moreover, specific antibodies produced against the VapA-specific peptid...
1 14 15 16 17 18 31